Table 3.
Radical radiotherapy or radiochemotherapy for invasive bladder cancer
| Study | Patients (n) | Stage | Experimental arm | Control arm | 3-to 5-year OS (%) | 3-to 5-year DSS (%) |
|---|---|---|---|---|---|---|
| Rödel et al. (2002) | 415 | T1-T4 | TUR + RCT (DDP/CBP/PF) n = 289 | TUR + RT n = 126 | 51 | 56 |
| Atasoy et al. (2014) | 26 | T2-T4a | RCT (GEM) | 58.5 | 59.5 | |
| James et al. (2012) | 360 | T2-T4a | RCT (MMC + 5Fu) n = 182 | RT alone n = 178 | 48 VS. 35 | |
| Choudhury et al. (2011) | 50 | T2-T3 | RCT (GEM) | 75 | 82 | |
| Mitin et al. (2013) | 93 | T2-T4a | TUR + RCT (DDP + TAX) + GTP n = 46 | TUR + RCT (DDP + 5Fu) + GTP n = 47 | 71 VS. 75 | |
| Hoskin et al. (2010) | 333 | T1G3-T4a | RCT (CON) n = 168 | RT alone n = 165 | 59 VS. 46 | |
| Kaufman et al. (2000) | 34 | T2-T4a | TUR + RCT (PF) | 83 | ||
| Nowak-Sadzikowska et al. (2013) | 35 | T2-T4a | TUR + NEO (GP/GC) + RT + DDP | 75 VS. 66 | 81 VS. 71 |
OS = overall survival, DSS = disease-specific survival, TUR = transurethral resection, RCT = radiochemotherapy, RT = radiotherapy, GEM = gemcitabine, MMC = mitomycin C, CON = carbogen and nicotinamide, NEO = neoadjuvant, MCV = methotrexate, cisplatin, vinblastine, DDP = cisplatin, CBP = carboplatin, PF = cisplatin and fluorouracil, GP = gemcitabine, cisplatin, GC = gemcitabine, carboplatin, GTP = gemcitabine + paclitaxel + cisplatin-.